Background

David J Brooks MD DSc FRCP(UK) FMedSci (UK) FEAN is Professor of Neurology and PET Clinical Science,  Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, and also Visiting Professor of Neurology in the Department of Medicine, Imperial College London and part-time Professor of Neurology at Dept of Nuclear Medicine, Aarhus University, Denmark. He is on the Grant Awards Board of Alzheimer Research UK and the Weston Brain Institute. He was Chairman of the European Research Council Neuroscience Panel  (Advanced Grants) and was a reviewer for JPND 2020 and 2022. He was also previously on the Biomedical Research Advisory Panel of Alzheimer UK  and Chairman of the Scientific Advisory Boards of Parkinson’s UK,. He served on the advisory panels of the Finnish Acadeny (Neuroscience) and the German Dementia and Parkinson Kompetenz Networks.

He was  a member of the NMRC International Expert Panel Singapore and was Chairman of the NUHS Scientific Advisory Panel. He was a member of the Scientific Advisory Board of the Michael J. Fox Foundation for Parkinson's Disease Research (2002-2006), UK Medical Research Council Neuroscience and Mental Health Board (2004-2007), Wellcome Trust Neuroscience Panel (2001-2003) and was Chairman of the Scientific Issues Committee of the Movement Disorder Society (1998-2002).

David is the UK Editor of Current Neuropharmacology. He was an Associate Editor of Brain and Molecular Imaging and Biology. He is on the Editorial Boards of Neurology - Clinical Practice, Journal of Parkinson’s Disease, Synapse, and NPJ Parkinson's Disease. He was on the Editorial Boards of Annals of Neurology, Movement Disorders, and Parkinsonism and Related Disorders. In 2001 he was elected a Fellow of the Academy of Medical Science, UK and a Fellow of the American Neurology Association. In 2018 he was elected a Fellow of the European Academy of Neurology. His research involves the use of positron emission tomography and magnetic resonance imaging to diagnose and study the progression of Alzheimer’s and Parkinson’s disease and his work is on the highly cited list with an h index of 123. He has been a recipient of  a Danish Alzheimer Foundation Prize, the Kuhl-Lassen award  (Society of Nuclear Medicine), and was invited to give the Ramon Y Cajal Lecture (Spanish Academy of Medicine), the Stahn Fahn Lecture (International Movement Disorder Society) and Cotzias Lecture (Spanish Neurology Society) Lectures. He is a consultant for GE Healthcare, Biogen, and previously Plexxikon, and GenePod.

Area of expertise: Neuroimaging, Parkinson's and Alzheimer's diseases

Google Scholar: Click here.

Selected reports:

1.      Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann. Neurol. 1990; 28: 547-555

2.      Koepp MJ, … Brooks DJ, … Grasby PM. Evidence for striatal dopamine release during a video game. Nature 1998; 393: 266-268.

3.      Cagnin A, Brooks DJ, et al. In vivo measurement of microglial  activation  in dementia. Lancet  2001;  358: 461-467.

4.      Gill SS, … Brooks DJ, … Heywood  P. Direct brain infusion of glial cell line-derived neu rotrophic  factor  (GDNF)  in  Parkinson's  Disease.  Nature Medicine 2003; 9: 589-595.

5.      Rinne JO, Brooks DJ, et al. [11C]PiB PET supports reduced cortical fibrillar Ag  in Alzheimer's disease patients  treated  with  bapineuzumab. Lancet Neurol 2010;  9:  363-372.

6.      Piccini P, Brooks DJ, Bjorkl und A, Gunn RN, Grasby PM, Rimoldi 0, Brundi n P, Hagell P, Rehncrona S, Widner H, Lindvall O. Dopamine release from nigral tra nsplants visualised in vivo in a Parkinson's patient. Nature Neuroscience 1999;  2:  1137-1140. 

7.    Rascol O, Brooks DJ, Korczyn AD, De Deyn P, Clarke C, Lang AE. Dyskinesia in Parkinson's Disease: A 5-Year Study of ropinirole versus levodopa. New Eng.J Med. 2000; 342: 1484-1491.